by Madaline Spencer | Nov 26, 2024
Anne Marie Morse, DO, of Geisinger Health, discusses the U.S. Food and Drug Administration (FDA) approval of Lumryz (sodium oxybate) for the treatment of cataplexy or excessive daytime sleepiness in patients with narcolepsy ages 7 years and older. ...
by Madaline Spencer | Nov 25, 2024
Richard Nowak, MD, and Director of Myasthenia Gravis Clinic at Yale University, discusses data from the MINT study for myasthenia gravis (MG). MG is a chronic autoimmune neuromuscular disease characterized by weakness of the skeletal muscles. The...
by Madaline Spencer | Nov 22, 2024
Ratna Bhavaraju-Sanka, MD, Chief of Neuromuscular Medicine at UT Health San Antonio, discusses Vyvgart’s (efgartigimod alfa) impact on myasthenia gravis (MG) patients. MG is a chronic autoimmune neuromuscular disease characterized by weakness of the...
by Madaline Spencer | Nov 21, 2024
Sabrina Sacconi, MD, PhD, Head of Neuromuscular Disease at Nice University Hospital, discusses recent guidelines for myasthenia gravis (MG). MG is a chronic autoimmune neuromuscular disease characterized by weakness of the skeletal muscles. The condition...
by Madaline Spencer | Nov 20, 2024
Emily Milligan, Executive Director of The Barth Syndrome Foundation, discusses the U.S. Food and Drug Administration’s (FDA) recommendation of approval for Barth syndrome treatment, elamipretide. Barth syndrome is a rare metabolic and neuromuscular...
